Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:ARCT NASDAQ:JANX NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.27-2.9%$5.63$1.85▼$7.18$888.03M1.222.17 million shs4.73 million shsARCTArcturus Therapeutics$7.61-4.0%$7.97$5.85▼$24.17$225.11M2.36445,684 shs393,868 shsJANXJanux Therapeutics$13.99-4.1%$14.52$12.12▼$35.34$889.76M2.53954,077 shs725,730 shsXNCRXencor$11.23-5.5%$12.16$6.92▼$18.69$880.81M0.93708,093 shs708,874 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+2.95%+5.08%-2.96%+2.76%+166.99%ARCTArcturus Therapeutics-1.89%+10.53%-9.97%-1.77%-38.48%JANXJanux Therapeutics-1.23%-0.76%+0.49%+7.22%-39.22%XNCRXencor-0.67%+4.33%-7.01%-1.83%+53.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.27-2.9%$5.63$1.85▼$7.18$888.03M1.222.17 million shs4.73 million shsARCTArcturus Therapeutics$7.61-4.0%$7.97$5.85▼$24.17$225.11M2.36445,684 shs393,868 shsJANXJanux Therapeutics$13.99-4.1%$14.52$12.12▼$35.34$889.76M2.53954,077 shs725,730 shsXNCRXencor$11.23-5.5%$12.16$6.92▼$18.69$880.81M0.93708,093 shs708,874 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+2.95%+5.08%-2.96%+2.76%+166.99%ARCTArcturus Therapeutics-1.89%+10.53%-9.97%-1.77%-38.48%JANXJanux Therapeutics-1.23%-0.76%+0.49%+7.22%-39.22%XNCRXencor-0.67%+4.33%-7.01%-1.83%+53.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.43Hold$16.00186.74% UpsideARCTArcturus Therapeutics 2.67Moderate Buy$25.44227.47% UpsideJANXJanux Therapeutics 2.60Moderate Buy$45.85218.16% UpsideXNCRXencor 2.40Hold$24.50107.63% UpsideCurrent Analyst Ratings BreakdownLatest ARCT, JANX, ANNX, and XNCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.005/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.005/11/2026JANXJanux Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$22.005/11/2026XNCRXencor JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$13.00 ➝ $14.005/8/2026JANXJanux Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $26.005/8/2026JANXJanux Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$45.00 ➝ $36.005/8/2026JANXJanux Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$68.00 ➝ $58.005/6/2026XNCRXencor Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/4/2026JANXJanux Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/28/2026JANXJanux Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $28.004/22/2026JANXJanux Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 6/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$1.42 per shareN/AARCTArcturus Therapeutics$82.03M2.69N/AN/A$7.53 per share1.03JANXJanux Therapeutics$10M87.87N/AN/A$15.91 per share0.91XNCRXencor$97.36M8.99N/AN/A$8.90 per share1.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$206.69M-$1.22N/AN/AN/AN/A-101.19%-75.99%8/13/2026 (Estimated)ARCTArcturus Therapeutics-$65.78M-$2.81N/AN/AN/A-143.80%-36.55%-28.40%8/10/2026 (Estimated)JANXJanux Therapeutics-$113.62M-$1.84N/AN/AN/AN/A-12.93%-12.23%8/6/2026 (Estimated)XNCRXencor-$91.92M-$2.29N/AN/AN/A-177.10%-28.77%-20.52%8/5/2026 (Estimated)Latest ARCT, JANX, ANNX, and XNCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ANNXAnnexon-$0.30-$0.23+$0.07-$0.23$5.50 millionN/A5/7/2026Q1 2026ARCTArcturus Therapeutics-$1.0320-$0.95+$0.0820-$0.95$6.30 million$2.06 million5/7/2026Q1 2026JANXJanux Therapeutics-$0.5202-$0.39+$0.1302-$0.39$4.36 million$3.73 million5/6/2026Q1 2026XNCRXencor-$0.7468-$1.71-$0.9632-$1.71$27.86 million$4.52 million3/30/2026Q4 2025ANNXAnnexon-$0.32-$0.28+$0.04-$0.28$3.25 millionN/A3/3/2026Q4 2025ARCTArcturus Therapeutics-$0.92-$1.03-$0.11-$1.0230$14.32 million$7.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AARCTArcturus TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A6.356.35ARCTArcturus TherapeuticsN/A6.316.31JANXJanux TherapeuticsN/A17.0117.01XNCRXencorN/A6.576.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AARCTArcturus Therapeutics94.54%JANXJanux Therapeutics75.39%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%ARCTArcturus Therapeutics17.80%JANXJanux Therapeutics7.90%XNCRXencor4.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60163.84 million146.95 millionOptionableARCTArcturus Therapeutics18028.42 million23.36 millionOptionableJANXJanux Therapeutics3060.98 million56.17 millionOptionableXNCRXencor28074.14 million70.38 millionOptionableARCT, JANX, ANNX, and XNCR HeadlinesRecent News About These CompaniesIncyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trialMay 30 at 8:19 PM | seekingalpha.comJefferies Financial Group Inc. Purchases 620,440 Shares of Xencor, Inc. $XNCRMay 25, 2026 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Hold" from BrokeragesMay 24, 2026 | americanbankingnews.comXencor IncMay 18, 2026 | money.usnews.comXencor, Inc. $XNCR Shares Sold by UBS Group AGMay 17, 2026 | marketbeat.comXencor (XNCR) Receives a Buy from Wells FargoMay 15, 2026 | theglobeandmail.comXencor, Inc. Common Stock (XNCR)May 13, 2026 | nasdaq.comXencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comXencor (NASDAQ:XNCR) Price Target Raised to $14.00 at JPMorgan Chase & Co.May 11, 2026 | marketbeat.comXencor (NASDAQ:XNCR) Rating Lowered to Strong Sell at Wall Street ZenMay 9, 2026 | marketbeat.comThese Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under ThreatMay 8, 2026 | finance.yahoo.comXencor (NASDAQ:XNCR) Downgraded by Zacks Research to "Strong Sell"May 8, 2026 | marketbeat.comXencor: Q1 Earnings SnapshotMay 6, 2026 | ctpost.comCXencor (XNCR) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comXencor (NASDAQ:XNCR) Releases Earnings Results, Misses Estimates By $1.06 EPSMay 6, 2026 | marketbeat.comXencor Reports First Quarter 2026 Financial ResultsMay 6, 2026 | businesswire.comXencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026May 6, 2026 | marketbeat.comXencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 TranscriptMay 5, 2026 | seekingalpha.comXencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 - SlideshowMay 5, 2026 | seekingalpha.comXencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDWMay 4, 2026 | businesswire.comJP Morgan Downgrades Xencor (XNCR)March 25, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARCT, JANX, ANNX, and XNCR Company DescriptionsAnnexon NASDAQ:ANNX$5.26 -0.16 (-2.86%) As of 12:45 PM Eastern This is a fair market value price provided by Massive. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Arcturus Therapeutics NASDAQ:ARCT$7.60 -0.32 (-3.98%) As of 12:45 PM Eastern This is a fair market value price provided by Massive. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Janux Therapeutics NASDAQ:JANX$13.98 -0.61 (-4.15%) As of 12:45 PM Eastern This is a fair market value price provided by Massive. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Xencor NASDAQ:XNCR$11.23 -0.65 (-5.47%) As of 12:45 PM Eastern This is a fair market value price provided by Massive. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for Investors How the Latest Federal Contract Boosts D-Wave's Prospects 5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to Wait Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance MarketBeat Week in Review – 05/25 - 05/29 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
